With expansion a prime focus for businesses worldwide, many are looking towards rapidly establishing new regions of growth, particularly in Asia, Pacifi c Rim countries.
The latest business developments from across Asia by Heather Hobbs To appear in our next issue, send your Business and Financial News stories to
heather@intlabmate.com
This section of International Labmate will especially look at the success of both Asian and European companies with established premises or business partnerships, highlighting the opportunities that exist while realising
potential for other companies to move into export markets.
Robotics speeds connectivity between medical professionals
marks the start of a new era for treatment in our fi eld,” said Professor Yundai Chen.
Professor Yundai Chen (Beijing) and Professor Yining Yang (Urumqi) perform First In Human robotic coronary angioplasty. (Credit: Robocath)
French robotic platform developers Robocath, specialising in solutions for treating cardiovascular diseases were pivotal to a medical procedure carried out simultaneously in Bejing and Urumqi 1,700 miles (2,800km) away. Two interventional cardiologists, Professor Yundai Chen in Beijing and Professor Yining Yang in Urumqi, the capital of the Xinjiang Uygur Autonomous Region, performed the First-in-Human robotic coronary angioplasty entirely using a 5G connection with the R-One™ robotic platform.
“I feel honoured to have been part of this world-fi rst- in-human procedure in the fi eld of interventional medicine. Its success opens up the possibility of future long-distance cardiovascular treatment options. China currently has over 2,000 catheterisation laboratories, but that’s still not enough to cover the whole country. With the help of robotics, we believe we can treat more patients faster and more effectively. Another advantage is that the robot can position the stent with exceptional accuracy. I’m excited to continue this partnership, which I believe
“This procedure shows the world the feasibility and safety of coronary angioplasty at very great distances, thanks to a perfectly stable and controlled communication system. The team at the People’s Hospital of Xinjiang Uygur Autonomous Region is extremely proud to have played a part in this phenomenal technological achievement, which has the potential to revolutionise interventional medicine,” added Professor Yining Yang.
“At Robocath, we are committed to developing smart connected robotic platforms that improve the treatment of cardiovascular diseases – the leading cause of death worldwide. Currently, these emergencies, including stroke, can remain untreated within a reasonable timeframe due to geographical remoteness and the small number of dedicated care centres. Robotic solutions remove these barriers entirely and ensure patients are treated quickly and to a very high standard by medical experts. From a specialist medical centre, physicians will be able to perform operations on patients located in outlying emergency units. There are still several challenges to face before this type of treatment can be widely adopted, particularly in terms of organisation and legal liability. However, we are convinced that the future of interventional medicine lies with robotics. Its remote connection module will considerably accelerate expansion, particularly in vast territories such as China,” stated company CEO Lucien Goffart.
More information online:
ilmt.co/PL/Ovd4 61870pr@reply-direct.com
Partnership provides access to single cell handling platforms
Oxford-based iotaSciences has signed an exclusive distribution agreement with Quantum Design China, a subsidiary of Quantum Design International, for iotaSciences proprietary single cell handling platforms in China.
“We are pleased to now offer customers in China access to iotaSciences platforms, which allows scientists to access highly user-friendly, reliable, and powerful single cell handling technologies and solutions with unique capabilities that greatly simplify and facilitate breakthrough advances in cell biology and gene therapy” said Lambert Cao, General Manager of Quantum Design China (Beijing). “We look forward to working closely with the iotaSciences team to introduce this unique technology to the rapidly expanding fi eld of single cell biological applications.”
Ed Walsh, iotaSciences Founding Director & Chief Innovation Offi cer commented: “We are highly excited about this next step with Quantum Design China to see our innovative technology being deployed across the Chinese scientifi c community. Our proprietary fl uid-shaping technology has translated very well into tangible user benefi ts for single-cell handling workfl ows as required in many frontiers research fi elds including CRISPR, iPSCs and gene therapy workfl ows.”
Hubs to improve health outcomes across the globe
At a meeting on science, technology and health cooperation between the UK and the Association of South East Asian Nations (ASEAN) held in November, UK Minister for Health and Secondary Care, Will Quince, announced four new hubs that will address challenges of vaccine manufacturing and delivery in developing countries. The meeting included the Secretary General of ASEAN, Dr Kao Kim Hourn and former Minister for Science, Research and Innovation George Freeman.
Communicable disease epidemics are still a major threat to public health globally. They are responsible for half of all deaths in low and middle-income countries (LMICs). It is estimated that 25 million children are under or unvaccinated. However, vaccines have now been developed for more than 20 life threatening diseases.
The hubs will be led by Imperial College London, University College London, University of Oxford and The University of Sheffi eld working with experts from across Africa, Asia and Latin America. Together, they will use the lessons from the global rollout of COVID vaccines to improve the processes of manufacture and distribution in LMICs.
The vaccine hubs have received a share of £33 million of UK aid funding via the Department of Health and Social Care (DHSC), and a further £1.5 million from the Engineering and Physical Sciences Research Council
(EPSRC).They will be part of the UK Vaccine Network (UKVN) project, which aims to develop vaccines for diseases with epidemic potential in LMICs.
Professor Miles Padgett, Interim Executive Chair of EPSRC, said: “These hubs will improve immunisation in low and middle-income countries by addressing challenges in the way vaccines are made and delivered.
“The Department of Health and Social Care and EPSRC are funding research that tackles large-scale, complex challenges and improves health outcomes across the globe.
UK Health Minister Will Quince, said: “I’m thrilled that the UK is building on its strong working relationship with global researchers by funding these innovative vaccine hubs, which will support partners across Africa and South East Asia to improve vaccine manufacturing capability.
“These innovative partnerships between British universities and vaccine developers – with £33 million of UK aid funding – will ensure vaccines are accessible to everyone in need, and allow us to future-proof health systems both here and abroad by accelerating the availability of new vaccines for future pandemics.”
More information online:
ilmt.co/PL/bVd0 61872pr@reply-direct.com
Does your company sell or wish to sell laboratory products and services to the economies of Asia?
Are you looking for local distributors and agents to represent you?
If so, why not advertise your products in our market-leading journal Lab Asia.
Email:
info@intlabmate.com
Dr Michael Lutz, iotaSciences recently appointed CEO added: “This partnership with Quantum Design China is another key milestone for the company´s future development path after the recent acceleration of its commercial activities leading to a doubling of its installed base in the last year. Quantum Design China is the ideal partner for us to team up with given its in-depth knowledge of optimally serving academic and industrial scientists in the life science market in China.”
More information online:
ilmt.co/PL/92YB 61873pr@reply-direct.com
Business
Opportunities Asia
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68
